Sanofi reports setbacks to Denali, Kymab and Principia assets, delivering mix of misses and halts

Sanofi has reported setbacks to a trio of candidates bought in by its business development team, halting work or posting negative data on assets picked up from Denali Therapeutics, Kymab and Principia Biopharma.